glaxosmithkline
Was Dr. Oz's Apple Juice Arsenic 'Crisis' Just a Ratings Ploy?
11:00AM 9/22/2011
Last week, TV host Dr. Mehmet Oz took on apple juice, declaring that the classic drink may be slowly poisoning America's children with arsenic. But the FDA and the juice companies have credibly refuted his claims. So was Dr. Oz's announcement meant to be a legitimate health warning, or just a cynical attempt to boost ratings?
FDA Approves First New Lupus Drug in Half a Century
7:15PM 3/09/2011
The Food and Drug Administration on Wednesday approved the first new drug to treat lupus in 56 years. It's not terribly effective: It only worked for 35% of the patients tested. But experts say the approval could prompt the development of more effective drugs.
The Sheen Index: Where Charlie's Meltdown Is Fuel for Business
1:30PM 3/02/2011
Economy, People, Investing, Media, General Electric , Time Warner, Altria Group
While painful (for most folks) to watch, the actor's explosion has created a bonanza for the tabloid mill. But on a broader level, Sheen has also offers a potential shot in the arm for companies across the spectrum, from media to pharmaceuticals. Hey Viacom, how about Charlie's Family?
Glaxo Faces First of Many Possible Avandia Trials
12:00PM 1/24/2011
Company News, Columns, Investing, GlaxoSmithKline, Stocks in the News
Did GlaxoSmithKline's blockbuster diabetes drug Avandia cause fatal heart attacks? The first federal trial of an Avandia lawsuit began this morning in Philidelphia. As many as 50,000 more lurk in the wings.
GlaxoSmithKline admits problems with its drugs
3:00PM 10/27/2010
After years of American drugmakers touting the benefits of U.S. drugs and warning about buying cheaper drugs from somewhere else, a major U.S. drugmaker is admitting that some of its drugs may not have been so good after all.
In what was a revealing and embarrassing admission, GlaxoSmithKline...
Diabetes Drug Avandia Gets No Sugar from Regulators
8:00PM 9/23/2010
GlaxoSmithKline's Avandia diabetes drug got hit with a double whammy from regulators on both sides of the pond Thursday. The European Medicines Agency announced plans to yank the drug from the market in the coming months, while U.S. officials placed greater restrictions on its use.
Novartis's New Lung Disease Drug Trumps GSK's Advair in Study
12:36PM 9/20/2010
Company News, Health Care, GlaxoSmithKline, Novartis, Stocks in the News
Shares of Swiss pharmaceutical company Novartis were up about 1.5% in morning trading Monday following its announcement over the weekend that its Onbrez Breezhaler was found to be more effective at treating lung disease than a standard medicine from GlaxoSmithKline.
Legal Briefing: Ban on Possession of Guns Without Serial Numbers Ruled Constitutional
1:08AM 7/30/2010
In a case that tested the boundaries of the Supreme Court's recent expansion of Second Amendment gun rights, the Third Circuit Court of Appeals ruled that some limits still apply: A federal law banning the possession of a gun with an obliterated serial number is constitutional, the court said.
The U.S. Food and Drug Administration warns that more than 25,000 asthma inhalers stolen last year from a pharmaceutical warehouse in Virginia have worked their way to pharmacy shelves and may not be safe or effective.
The Advair Diskus inhalers, manufactured by GlaxoSmithKline, were stolen from a...
FDA panel recommends keeping diabetes drug Avandia on the market
11:30AM 7/15/2010
GlaxoSmithKline's diabetes drug Avandia should remain on the market but with new restrictions due to possible heart risks, says a federal panel of health experts.
The U.S. Food and Drug Administration advisers voted 20-12 to keep the medicine available -- 10 panelists also recommended limiting who...
More Stories
Next Page →Market Movers
| Symbol | Last | Change / % | Volume |
|---|
Most Actives
| 8.08 | -0.11 -1.28% | 184.54M | |
| 2.21 | +0.27 +13.66% | 107.06M | |
| 12.45 | -0.25 -1.93% | 35.97M | |
| 18.84 | -0.30 -1.54% | 33.77M |
% Gainers
| 31.71 | +7.81 +32.68% | 15.75M | |
| 89.60 | +13.21 +17.29% | 10.41M | |
| 2.21 | +0.27 +13.66% | 107.06M | |
| 10.55 | +1.15 +12.23% | 2.78M |
% Losers
DailyFinance Wire
- 4 Money-Etiquette Questions Answered
- Walmart's New Health Food Push: Is It Too Hard to Swallow?
- Newlyweds, Don't Let the IRS Spoil Your Honeymoon
- Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger
- Why Groupon Will Never Be Great Again
- Why Used Car Bargains Are Getting Harder to Find
- 5 Reasons Facebook Stock May Be a Better Buy Than You Think
Newswire
- Greek PM says default would lead to 'chaos'
- Budget deficit drops to $27 billion in January
- Turbo-traders take Bank of America for a ride
- Stocks fall sharply as Greek deal is held up
- Bernanke: Weak housing has hurt consumer...
- Trade deficit widens to $48.8 billion in...
- Feds investigate door fires in 2007 Camrys,...
- Review: Netflix and Hulu's new scripted...
- Mid-day Movers (CIE, AMRS, IPSU, MOVE, LNKD)
- Petrobras Shares Volatile on $225 Billion Development Plan (PBR)
- Morning Movers (CIE, ALU, LNKD, AMRS, XIDE)
- AEP Dividend Growth Still Looks Safe Ahead (AEP)
- Arch Coal Tumbles on Earnings, Forecast (ACI, ANR, PCX, BTU, CNX)
- 2011 Trade Deficit Hits 3-Year High, Over $550 Billion
- Today’s Best Market Rumors (2/10/2012) Apple iPad, Google Entertainment
- Top Analyst Upgrades & Downgrades (ALTR, AMSC, BIIB, CELG, COH, CSTR, COP, FSLR, GILD, HAIN, MA, RF, TRLG)
Follow Us
